In hepatitis B, where treatment is usually long term and where viral resistance is a significant problem, the issue is not so much whether one can stop early because of either a high likelihood of
success or the inevitability of
ultimate failure, but optimization of treatment
to ensure the greatest likelihood of long-term viral suppression with a minimal risk of resistance."
2. "resistance is much more likely to occur when viral suppression is incomplete."